Compound: Givinostat
SMILES: O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc3ccc(C(=O)NO)cc3
InChIKey: YALNUENQHAQXEA-UHFFFAOYSA-N
Synonyms: Givinostat, 497833-27-9, ITF-2357, Gavinostat, 5P60F84FBH, [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate, DUVYZAT, DTXSID70198049, givinostatum, (6-(diethylaminomethyl)naphthalen-2-yl)methyl N-(4-(hydroxycarbamoyl)phenyl)carbamate, RefChem:143259, DTXCID50120540, ITF2357, Givinostat [INN], Givinostat free base, (6-((diethylamino)methyl)naphthalen-2-yl)methyl (4-(hydroxycarbamoyl)phenyl)carbamate, UNII-5P60F84FBH, [4-[(Hydroxyamino)carbonyl]phenyl]carbamic acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester, CHEMBL1213492, (6-((Diethylamino)methyl)naphthalen-2-yl)methyl(4-(hydroxycarbamoyl)phenyl)carbamate, {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate, 4-[(Hydroxyamino)carbonyl]phenyl]carbamic acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester, Carbamic acid, (4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, 497833-27-9 (free base), Givinostat [WHO-DD], Givinostat (USAN/INN), GIVINOSTAT [USAN], GTPL7490, orb3027338, SCHEMBL1555814, SCHEMBL29361624, CHEBI:94187, BDBM50105329, EBC-07919, AKOS030526824, CS-4727, DB12645, EX-5958, [6-(diethylaminomethyl)-2-naphthyl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate, {6-[(diethylamino)methyl]naphthalen-2-yl}methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate, AC-31380, BCB04_000011, HY-14842, DB-310739, NS00069327, D12742, EN300-260030, G13884, Q426257, BRD-K13810148-001-01-3, BRD-K13810148-311-03-2, Carbamic acid, N-[4-[(hydroxyamino)carbonyl]phenyl]-, [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester, QCM
Theoretical properties:
molecular_formula: C24H27N3O4
molecular_weight: 421.5 g/mol
exact_mass: 421.20015635 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 9
heavy_atom_count: 31
topological_polar_surface_area: 90.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Givinostat is a member of the class of naphthalenes that is naphthalene substituted by ({[4-(hydroxycarbamoyl)phenyl]carbamoyl}oxy)methyl and (diethylamino)methyl groups at positions 2 and 6, respectively. It is a histone deacetylase inhibitor indicated for individuals diagnosed with Duchenne muscular dystrophy. It has a role as an antineoplastic agent, an angiogenesis inhibitor, an EC 3.5.1.98 (histone deacetylase) inhibitor, an anti-inflammatory agent and an apoptosis inducer. It is a member of benzenes, a carbamate ester, a hydroxamic acid, a member of naphthalenes and a tertiary amino compound. It is a conjugate base of a givinostat(1+).
chebi: A member of the class of naphthalenes that is naphthalene substituted by ({[4-(hydroxycarbamoyl)phenyl]carbamoyl}oxy)methyl and (diethylamino)methyl groups at positions 2 and 6, respectively. It is a histone deacetylase inhibitor indicated for individuals diagnosed with Duchenne muscular dystrophy.
chembl: GIVINOSTAT is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Givinostat, sold under the brand name Duvyzat is a medication used for the treatment of Duchenne muscular dystrophy. It is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.
The most common side effects include diarrhea, abdominal pain, low platelets (thrombocytopenia), nausea/vomiting, an increase in triglycerides (a type of fat in the body) (hypertriglyceridemia), and fever.
Givinostat was approved for medical use in the United States in March 2024. Givinostat is the first nonsteroidal medication approved by the US Food and Drug Administration (FDA) to treat people with all genetic variants of Duchenne muscular dystrophy. The FDA considers it to be a first-in-class medication.